Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Contrasting effects of sunitinib within in vivo models of metastasis.

Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, Frentzas S, Bird D, Sharpe K, van Weverwijk A, Robertson D, Soffe J, Erler JT, Pili R, Springer CJ, Mather SJ, Reynolds AR.

Angiogenesis. 2012 Dec;15(4):623-41. doi: 10.1007/s10456-012-9291-z. Epub 2012 Jul 28.

2.

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.

Chung AS, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D, Komuves L, Peale F, Ferrara N.

J Pathol. 2012 Aug;227(4):404-16. doi: 10.1002/path.4052. Epub 2012 Jul 3.

PMID:
22611017
3.

Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.

Thézé B, Bernards N, Beynel A, Bouet S, Kuhnast B, Buvat I, Tavitian B, Boisgard R.

BMC Cancer. 2015 Jul 22;15:534. doi: 10.1186/s12885-015-1540-2.

4.

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P.

Int Immunopharmacol. 2011 Jul;11(7):856-61. doi: 10.1016/j.intimp.2011.01.030. Epub 2011 Feb 11.

5.

Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.

Maita S, Yuasa T, Tsuchiya N, Mitobe Y, Narita S, Horikawa Y, Hatake K, Fukui I, Kimura S, Maekawa T, Habuchi T.

Int J Cancer. 2012 Feb 1;130(3):677-84. doi: 10.1002/ijc.26034. Epub 2011 Jun 10.

6.

Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.

Rovida A, Castiglioni V, Decio A, Scarlato V, Scanziani E, Giavazzi R, Cesca M.

Mol Cancer Ther. 2013 Oct;12(10):2237-47. doi: 10.1158/1535-7163.MCT-13-0244. Epub 2013 Aug 5. Erratum in: Mol Cancer Ther. 2014 Jan;13(1):270.

7.

Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.

Bagi CM, Gebhard DF, Andresen CJ.

Eur J Gastroenterol Hepatol. 2012 May;24(5):563-74. doi: 10.1097/MEG.0b013e328350916f.

PMID:
22314934
8.
9.

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.

Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, Long JE, Hamilton P, McNutt A, Kasman I, Nannini MA, Reslan HB, Cao TC, Ho CC, Barck KH, Carano RA, Foreman O, Eastham-Anderson J, Jubb AM, Ferrara N, Johnson L.

J Pathol. 2012 Aug;227(4):417-30. doi: 10.1002/path.4053. Epub 2012 Jun 28.

PMID:
22611036
10.

Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.

Rautiola J, Lampinen A, Mirtti T, Ristimäki A, Joensuu H, Bono P, Saharinen P.

PLoS One. 2016 Apr 21;11(4):e0153745. doi: 10.1371/journal.pone.0153745. eCollection 2016.

11.

HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.

Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG.

Cancer Lett. 2012 Jul 1;320(1):48-55. doi: 10.1016/j.canlet.2012.01.026. Epub 2012 Jan 21.

PMID:
22269210
12.

Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.

Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W.

Clin Oncol (R Coll Radiol). 2011 Jun;23(5):339-43. doi: 10.1016/j.clon.2010.11.006. Epub 2010 Dec 4.

PMID:
21134733
13.

New perspectives: role of sunitinib in breast cancer.

Fratto ME, Imperatori M, Vincenzi B, Tomao F, Santini D, Tonini G.

Clin Ter. 2010;161(5):475-82. Review.

PMID:
20949248
14.

Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.

Tanaka Y, Shibata MA, Morimoto J, Otsuki Y.

Anticancer Res. 2011 Apr;31(4):1225-34.

PMID:
21508369
15.

Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.

Ströbel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A.

Br J Cancer. 2010 Jul 13;103(2):196-200. doi: 10.1038/sj.bjc.6605740. Epub 2010 Jun 22.

16.

Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.

Gandhi L, McNamara KL, Li D, Borgman CL, McDermott U, Brandstetter KA, Padera RF, Chirieac LR, Settleman JE, Wong KK.

Cancer Prev Res (Phila). 2009 Apr;2(4):330-7. doi: 10.1158/1940-6207.CAPR-08-0213. Epub 2009 Mar 31.

17.

Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.

de Brito LR, Batey MA, Zhao Y, Squires MS, Maitland H, Leung HY, Hall AG, Jackson G, Newell DR, Irving JA.

Leuk Res. 2011 Sep;35(9):1233-40. doi: 10.1016/j.leukres.2011.01.011. Epub 2011 Feb 11.

PMID:
21316102
18.

Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.

Wu CL, Ping SY, Yu CP, Yu DS.

Kaohsiung J Med Sci. 2012 Apr;28(4):194-203. doi: 10.1016/j.kjms.2011.06.020. Epub 2011 Sep 25.

19.
20.

Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.

Wang X, Zhang L, O'Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS.

Br J Cancer. 2013 Feb 5;108(2):319-26. doi: 10.1038/bjc.2012.591. Epub 2013 Jan 15.

Supplemental Content

Support Center